Cirrhosis News and Research

Latest Cirrhosis News and Research

Tioga Pharmaceuticals announces commencement of asimadoline Phase 2 study for treatment of pruritus

Tioga Pharmaceuticals, a clinical stage biotechnology company, today announced the initiation of a Phase 2 clinical study of asimadoline, a novel, well-studied kappa-opioid receptor specific agonist, for the treatment of pruritus or itching. The double-blind, placebo-controlled clinical study is designed to evaluate the safety, tolerability, and clinical efficacy of asimadoline in patients with pruritus due to atopic dermatitis and is being conducted at 20 clinical study centers in the United States.

11 Jun 2015

GSU scientists design new MRI technique for early detection of liver tumors

Scientists at Georgia State University with funding from the National Institute of Biomedical Imaging and Bioengineering have designed an imaging technique to detect early-stage liver tumors, and have proven it successful in mice.

10 Jun 2015

AWMSG recommends Daklinza (daclatasvir) for treatment of adult patients with chronic HCV infection

The All Wales Medicines Strategy Group has recommended Daklinza (daclatasvir) for the treatment of adult patients with chronic hepatitis C virus (HCV) infection. The recommendation is specifically for patients with advanced liver disease, for whom treatment options can be limited.

5 Jun 2015

miR-181b potential biomarker of replication, progression in chronic HBV

A Chinese team reports a correlation between serum levels of microRNA-181b and hepatitis B virus replication and disease progression in patients with chronic HBV infection.

1 Jun 2015

AbbVie announces new results from Phase 3 GIFT-I study in GT1b HCV infected Japanese patients

AbbVie presented new results from the Phase 3 GIFT-I study of its investigational, all-oral, interferon (IFN)- and ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir at the Annual Meeting of the Japan Society of Hepatology in Kumamoto, Japan.

27 May 2015

Risk prediction model can help target hepatitis C treatment to patients with most urgent need

A team of researchers at the University of Michigan Health System has developed a risk prediction model that helps identify which hepatitis C patients have the most urgent need for new anti-viral drugs.

22 May 2015

Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

Alnylam Pharmaceuticals, Inc. has announced that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease (alpha-1 liver disease).

19 May 2015

Monash University-led researchers call for HCV patients to gain improved access to effective drugs

In a letter to the Medical Journal of Australia published today, a Monash University-led team is asking for hepatitis C virus patients to gain improved access to drugs to prevent liver related deaths.

19 May 2015

Research leads way for noninvasive detection of early stage liver cancer

Led by Georgia State University, researchers have developed the first robust and noninvasive detection of early stage liver cancer and liver metastases, in addition to other liver diseases, such as cirrhosis and liver fibrosis.

15 May 2015

MD Anderson researchers find significant clinical variations among liver cancer patients

Significant clinical variations exist among patients with the most common type of liver cancer called hepatocellular carcinoma (HCC), depending on the viral cause of the disease -hepatitis B virus (HBV) or hepatitis C virus (HCV). These differences suggest that hepatitis status should be considered when developing treatment plans for newly diagnosed patients, according to researchers at The University of Texas MD Anderson Cancer Center.

14 May 2015

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

11 May 2015

New edition of WHO Essential Medicines List includes new treatments for hepatitis C, cancers and multi-drug TB

WHO today published the new edition of its Model List of Essential Medicines which includes ground-breaking new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia) and multi-drug resistant tuberculosis (TB), among others. The move opens the way to improve access to innovative medicines that show clear clinical benefits and could have enormous public health impact globally.

8 May 2015

WHO moves to improve access to lifesaving medicines for hepatitis C, Drug-resistant TB and cancers

The World Health Organization (WHO) today published the new edition of its Model List of Essential Medicines) which includes ground-breaking new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia) and multi-drug resistant tuberculosis (TB), among others...

8 May 2015

Hepatitis C common among HIV-positive patients in sub-Saharan Africa

A new study has found high levels of infection with hepatitis C (HCV) across Africa, particularly in people infected with HIV...

7 May 2015

Investigational three-drug combination clears hepatitis C in 93% of patients with liver cirrhosis

A 12-week dose of an investigational three-drug hepatitis C combination cleared the virus in 93 percent of patients with liver cirrhosis who hadn't previously been treated, according to a study in the May 5, 2015, issue of The Journal of the American Medical Association.

7 May 2015

Exalenz Bioscience investigates clinical utility of BreathID test to diagnose NASH

Exalenz Bioscience, a leader in developing and marketing of non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced the initiation of a clinical study evaluating the potential of its BreathID test to diagnose nonalcoholic steatohepatitis (NASH).

6 May 2015

New study finds high levels of HCV infection among HIV-infected people across Africa

A new study has found high levels of infection with hepatitis C (HCV) across Africa, particularly in people infected with HIV.

6 May 2015

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Phase 3 results presented today at The International Liver Congress 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with hepatitis C virus (HCV) infection with advanced cirrhosis and post-transplant recurrence.

27 Apr 2015

Sofosbuvir in combination with ribavirin/peginterferon achieves highest SVR rates in GT-3 HCV patients

Results presented today at The International Liver Congress 2015 demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date.

25 Apr 2015

Combination treatment effective for HCV genotype-1 mono-infected patients

Results presented today at The International Liver Congress 2015 show that the sofosbuvir (SOF)/daclatasvir (DCV) treatment combination is effective amongst hepatitis C virus (HCV) genotype-1 mono-infected patients. These results are significant because whilst other combinations have been widely reported on, there have been few data until now regarding the use of SOF/DCV combination in real world situations.

25 Apr 2015

Cirrhosis News and Research

Latest Cirrhosis News and Research

Tioga Pharmaceuticals announces commencement of asimadoline Phase 2 study for treatment of pruritus

GSU scientists design new MRI technique for early detection of liver tumors

AWMSG recommends Daklinza (daclatasvir) for treatment of adult patients with chronic HCV infection

miR-181b potential biomarker of replication, progression in chronic HBV

AbbVie announces new results from Phase 3 GIFT-I study in GT1b HCV infected Japanese patients

Risk prediction model can help target hepatitis C treatment to patients with most urgent need

Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

Monash University-led researchers call for HCV patients to gain improved access to effective drugs

Research leads way for noninvasive detection of early stage liver cancer

MD Anderson researchers find significant clinical variations among liver cancer patients

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

New edition of WHO Essential Medicines List includes new treatments for hepatitis C, cancers and multi-drug TB

WHO moves to improve access to lifesaving medicines for hepatitis C, Drug-resistant TB and cancers

Hepatitis C common among HIV-positive patients in sub-Saharan Africa

Investigational three-drug combination clears hepatitis C in 93% of patients with liver cirrhosis

Exalenz Bioscience investigates clinical utility of BreathID test to diagnose NASH

New study finds high levels of HCV infection among HIV-infected people across Africa

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Sofosbuvir in combination with ribavirin/peginterferon achieves highest SVR rates in GT-3 HCV patients

Combination treatment effective for HCV genotype-1 mono-infected patients

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Cirrhosis News and Research

Latest Cirrhosis News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in